IL6 and coronary artery disorder: Based on the RESCUE (Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition) results, Ridker and colleagues are conducting a new trial, ARTEMIS (A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack) (NCT06118281), to evaluate whether ziltivekimab can reduce recurrent cardiovascular events in patients with CAD.